ACADIA PHARMACEUTICALS INC. Cost of Goods Sold (Deprecated 2018-01-31)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Cost of Goods Sold (Deprecated 2018-01-31) of $2.15 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2018-05-04
- ACADIA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $2.15M, a 4.86% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $2.46M, a 44.07% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $2.13M, a 152.66% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $2.22M, a 322.81% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $9.08M, a 195.19% increase from fiscal 2016.
- ACADIA PHARMACEUTICALS INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $3.08M.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $2.15M 10-Q · filed 2018-05-04 | $4.61M derived: sum of 2 quarters · filed 2018-05-04 | $6.74M derived: sum of 3 quarters · filed 2018-05-04 | $8.97M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $4.59M derived: sum of 2 quarters · filed 2018-02-27 | $6.81M derived: sum of 3 quarters · filed 2018-02-27 | $9.08M 10-K · filed 2018-02-27 |
| 2017-09-30 | $2.13M 10-Q · filed 2017-11-07 | $4.36M derived: sum of 2 quarters · filed 2017-11-07 | $6.62M 10-Q · filed 2017-11-07 | $8.33M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | $2.22M 10-Q · filed 2017-08-08 | $4.49M 10-Q · filed 2017-08-08 | $6.19M derived: sum of 3 quarters · filed 2018-05-04 | $7.04M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $2.26M 10-Q · filed 2018-05-04 | $3.97M derived: sum of 2 quarters · filed 2018-05-04 | $4.81M derived: sum of 3 quarters · filed 2018-05-04 | $5.34M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.55M derived: sum of 2 quarters · filed 2018-02-27 | $3.08M derived: sum of 3 quarters · filed 2018-02-27 | $3.08M 10-K · filed 2018-02-27 |
| 2016-09-30 | $845.00K 10-Q · filed 2017-11-07 | $1.37M derived: sum of 2 quarters · filed 2017-11-07 | $1.37M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $526.00K 10-Q · filed 2017-08-08 | $526.00K 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |